Blackstone Inc. and private‑equity firm TPG announced on Tuesday, 2025‑10‑21, that they will acquire all outstanding shares of Hologic, a women’s‑health diagnostics company, for up to $18.3 billion. The deal values Hologic at $76 per share in cash, a price that represents a premium to the company’s recent trading levels.
The transaction expands Blackstone’s footprint in the medical diagnostics sector, adding a company that designs and manufactures a broad range of women’s health products, including screening tests and imaging equipment. The acquisition aligns with Blackstone’s strategy of investing in high‑growth, defensible healthcare businesses that generate stable cash flows and offer opportunities for operational improvements.
The deal is structured as a cash purchase financed jointly by Blackstone and TPG, with an expected closing in the coming months. The transaction will increase Blackstone’s healthcare portfolio, diversify its revenue base, and provide potential synergies through shared technology and distribution networks.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.